Yuan Yue, Wang Zheng, Nie Xin, Zhang Ping, Li Lin
Department of Oncology, Beijing Hospital; National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing 100730, China.
Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.
Zhongguo Fei Ai Za Zhi. 2022 Sep 20;25(9):696-700. doi: 10.3779/j.issn.1009-3419.2022.102.29.
Anaplastic lymphoma kinase (ALK) fusion gene is an important tumor driver gene of non-small cell lung cancer, accounting for about 5% of patients with non-small cell lung cancer, of which 97% are patients with lung adenocarcinoma. Since the first discovery of echinoderm microtubule associated protein-like 4 (EML4)-ALK fusion in patients with lung adenocarcinoma in 2007, a variety of ALK fusion partners have been detected. CLIP1-ALK fusion gene was detected by next generation sequencing (NGS) in this patient with advanced lung squamous cell carcinoma, and Alectinib and Ensartinib were taken orally on May 5, 2021. Aletinib was effective for this patient but the patients died on September 30, 2021. This is a report of lung squamous cell carcinoma patients with CLIP1-ALK fusion gene treated with ALK inhibitors. .
间变性淋巴瘤激酶（ALK）融合基因是非小细胞肺癌重要的肿瘤驱动基因，约占非小细胞肺癌患者的5%，其中97%为肺腺癌患者。自2007年首次在肺腺癌患者中发现棘皮动物微管相关蛋白样4（EML4）-ALK融合以来，已检测到多种ALK融合伴侣。该晚期肺鳞状细胞癌患者通过下一代测序（NGS）检测到CLIP1-ALK融合基因，并于2021年5月5日开始口服阿来替尼和恩沙替尼。阿来替尼对该患者有效，但患者于2021年9月30日死亡。本文报告了1例接受ALK抑制剂治疗的CLIP1-ALK融合基因肺鳞状细胞癌患者。
